CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Reaffirmed by Mizuho

Mizuho restated their buy rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a report released on Monday, AnalystRatings.com reports. They currently have a $16.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on the company. Cowen reaffirmed a buy rating on shares of CytomX Therapeutics in a research note on Wednesday, August 7th. Nomura reaffirmed a buy rating and set a $22.00 price objective on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Cantor Fitzgerald reaffirmed an overweight rating and set a $23.00 price objective (up from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd. Zacks Investment Research raised CytomX Therapeutics from a hold rating to a strong-buy rating and set a $14.00 target price for the company in a research note on Wednesday, July 17th. Finally, ValuEngine raised CytomX Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $20.22.

Shares of CytomX Therapeutics stock opened at $9.07 on Monday. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 0.26. CytomX Therapeutics has a 12 month low of $8.78 and a 12 month high of $24.34. The business has a fifty day simple moving average of $10.86 and a 200 day simple moving average of $11.68.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). CytomX Therapeutics had a negative return on equity of 77.05% and a negative net margin of 158.05%. The company had revenue of $9.01 million for the quarter, compared to analyst estimates of $15.11 million. As a group, equities research analysts expect that CytomX Therapeutics will post -2.07 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in CytomX Therapeutics by 6.3% during the fourth quarter. Bank of New York Mellon Corp now owns 185,552 shares of the biotechnology company’s stock worth $2,802,000 after buying an additional 11,007 shares during the period. Dimensional Fund Advisors LP purchased a new position in CytomX Therapeutics during the fourth quarter worth about $681,000. Geode Capital Management LLC boosted its stake in CytomX Therapeutics by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 566,901 shares of the biotechnology company’s stock worth $8,560,000 after buying an additional 52,736 shares during the period. Bank of America Corp DE boosted its stake in CytomX Therapeutics by 6.5% during the fourth quarter. Bank of America Corp DE now owns 55,574 shares of the biotechnology company’s stock worth $839,000 after buying an additional 3,416 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in CytomX Therapeutics by 376.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock worth $204,000 after buying an additional 10,650 shares during the period. 81.62% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: What is the Gross Domestic Product (GDP)?

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.